Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: Combined effect for both infections, an obtainable goal?

Antiviral Research

Volumn 42, Issue 1, 1999, Pages 71-76

  Wolters, Leonieke M M ^a   Niesters, Hubert G M ^a   De Man, Robert A ^a   Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hepatitis B virus; Human immunodeficiency virus; Lamivudine; Lamivudine withdrawal hepatitis; Resistance; Triple therapy

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; COTRIMOXAZOLE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; PRIORITY JOURNAL; REBOUND; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS MUTATION;

ANTI-HIV AGENTS; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RECURRENCE;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032961718     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00016-9     Document Type: Article

References (19)

1. Aye T.T., Bartholomeusz A., Shaw T., Bowden S., Breschkin A., McMillan J., Angus P., Locarnini S. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatol. 26:1997;1148-1153.
2. Bartholomew M.M., Jansen R.W., Jeffers L.J., Reddy K.R., Johnson L.C., Bunzendahl H., Condreay L.D., Tzakis A.G., Schiff E.R., Brown N.A. Hepatitis B-virus resistance to lamivudine given for a recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
3. Benhamou Y., Dohin E., Lunel-Fabiani F., Poynard T., Huraux J.M., Katlama C., Opolon P., Gentilini M. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet. 345:1995;396-397.
4. Benhamou Y., Katlama C., Lunel F., Coutellier A., Dohin E., Hamm N., Tubiana R., Herson S., Poynard T., Opolon P. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann. Intern. Med. 125:1996;705-712.
5. Boucher C.A., Cammack N., Schipper P., Schuurman R., Rouse P., Wainberg M.A., Cameron J.M. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:1993;2231-2234.
6. Carr A., Cooper D.A. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet. 349:1997;995-996.
7. de Man R.A., Bartholomeusz A.I., Niesters H.G.M., Zondervan P.E., Locarnini S.A. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J. Hepatol. 29:1998;669-675.
8. Eron J.J., Benoit S.L., Jemsek J., MacArthur R.D., Santana J., Quinn J.B., Kuritzkes D.R., Fallon M.A., Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New Engl. J. Med. 333:1995;1662-1669.
9. Gerlich W.H., Heermann U.H., Thomssen R. Quantitative assays for hepatitis B virus DNA: standardization and quality control. Viral. Hep. Rev. 1:1995;53-57.
10. Gilson R.J., Hawkins A.E., Beecham M.R., Ross E., Waite J., Briggs M., McNally T., Kelly G.E., Tedder R.S., Weller I.V. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 11:1997;597-606.
11. Honkoop P., de Man R.A., Heijtink R.A., Schalm S.W. Hepatitis B reactivation after lamivudine. Lancet. 346:1995;1156-1157.
12. Honkoop P., Niesters H.G.M., de Man R.A., Osterhaus A.D.M.E., Schalm S.W. Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns. J. Hepatol. 26:1997;1393-1395.
13. Honkoop, P., de Man, R.A., Niesters, H.G.M., Zondervan, P.E., Schalm, S.W., 1999. The management of severe acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine. Submitted.
14. Krogsgaard K., Lindhardt B.O., Nielsen J.O., Andersson P., Kryger P., Aldershvile J., Gerstoft J., Pedersen C. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology. 7:1987;37-41.
15. Ling R., Mutimer D., Ahmed M., Boxall E.H., Elias E., Dusheiko G.M., Harrison T.J. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
16. Niesters, H.G.M., Honkoop, P., Haagsma, E., de Man, R.A., Schalm, S.W., Osterhaus, A.D.M.E., 1998. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis. 177, 1382-1385.
17. Olano J.P., Borucki M.J., Wen J.W., Haque A.K. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin. Infect. Dis. 21:1995;973-976.
18. Sinicco A., Raiteri R., Sciandra M., Bertone C., Lingua A., Salassa B., Gioannini P. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand. J. Infect. Dis. 29:1997;111-115.
19. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., Tyrrell D.L.J. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.